FDA Warns of Myfortic and CellCept Birth Defect Risks
On Friday, the FDA posted an alert on their website to provide additional information to doctors about the possible risk of miscarriages and birth defects associated with the use of CellCept and Myfortic during pregnancy. A black box warning was added to the organ transplant medications in November 2007, but the FDA issued a second alert last week since the drugs are often prescribed “off-label” for unapproved uses, such as treating lupus, and many doctors remain unaware of the danger of fetal injury.
CellCept (mycophenolate mofetil) is manufactured by Roche, and Myfortic (mycophenolic acid) is manufactured by Novartis AG. Both drugs are are immunosuppressants, which are designed to prevent organ rejection following a transplant. Reports indicate that use during pregnancy could increase the risk of spontaneous abortions (miscarriages) and congential malformations, such as cleft lips, cleft palates and ear deformities.
According to data in the National Transplantation Pregnancy Registry (NTPR), out of 33 pregnant women exposed to CellCept, just under half of the pregnancies (15) resulted in a spontaneous abortion. For those that resulted in a live birth, four out of the 18 babies (22%) had malformations. For post-organ transplant women who were taking other immunosuppressive drugs, the NTPR data indicates only 4-5% of babies were born with structural malformations.
Did You Know?
Millions of Philips CPAP Machines Recalled
Philips DreamStation, CPAP and BiPAP machines sold in recent years may pose a risk of cancer, lung damage and other injuries.Learn More
Although there have been no official reports of Myfortic birth defects, since the drug is chemically similar to CellCept, the FDA has indicated the same risk of fetal injury could apply. The active pharmaceutical ingredient in CellCept is MMF (mycophenolate mofetil), which is an ester of MPA (metobolite mycophenolic acid), the active ingredient in Myfortic.
Warning Added for Progressive Multifocal Leukoencephalopathy to CellCept and Myfortic — AboutLawsuits.comJuly 2, 2008 at 3:45 am
[...] drugs have also been associated with increased risk of fetal injury, such as cleft palate, cleft lip and ear deformities, when taking during pregnancy. The [...]
"*" indicates required fields
More Top Stories
A new report indicates the U.S. Navy is struggling to process tens of thousands of Camp Lejeune water poisoning claims due to a lack of resources.
A group of plaintiffs have filed a motion with the U.S. JPML seeking consolidation of all Bard implanted port lawsuits before one judge for pretrial proceedings.
A Tepezza hearing loss lawsuit accuses the manufacturer of failing to provide adequate warning about the risks of the thyroid eye disease drug.